EXOS 25 - Pharmacom Labs

Exemestane developed by Pharmacia & Upjohn and approved by the FDA in 1999, it is sold under the brand name Aromasin and it is typically prescribed for postmenopausal women with breast cancer who no longer respond to tamoxifen. It is strong aromatase-inhibitors. It is created to stop the transformation of androgens to estrogens (by blocking the aromatase enzyme). With controlling ES-related side effects, during steroid cycles, it has gained popularity within the bodybuilding community. It has the ability to lowering serum estrogen levels by up to 85%.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about EXOS 25 by Pharmacom Labs, consult with your doctor or healthcare professional.